Current partner codePEPTIDESDE
NCT07525440·Not applicable·OBSERVATIONAL

Neural Respiratory Drive Combined With Pro-Brain Natriuretic Peptide (Pro-BNP) as Predictor of Deterioration After Lung Transplantation

Status

Completed

Phase

Not applicable

Enrollment

80

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

Lung transplantation has become a promising therapeutic option for various end-stage lung diseases. However, many factors such as infection, graft rejection, airway complications would cause deterioration and shorten the survival time. It is important to detect the deterioration early and receive treatment timely, which may enhance survival. We hypothesis the decreased neural respiratory drive(NRD) would be increased in the deterioration due to the aggravation of lung. Furthermore, pro-Brain Natriuretic Peptide(pro-BNP) has been reported to be associated with greater mortality after lung transplantation.For this reason, we investigated the NRD and pro-BNP before and after lung transplantation and during deterioration. 80 patients were recruited.They were end-stage lung disease patients admitted to hospital for lung transplantation. The NRD and pro-BNP were monitored before and after lung transplantation.we investigated the NRD and pro-BNP before and after lung transplantation and during deterioration.

Interventions

Treatment arms and agents.

OTHER

No Intervention: Observational Cohort

no intervention

Timeline

From registration to results.

  1. First posted

    Apr 13, 2026

  2. Study start

    Jan 1, 2016

  3. Primary completion

    Feb 1, 2026

  4. Study completion

    Feb 1, 2026

  5. Results posted

    Not reported

  6. Registry updated

    Apr 13, 2026

Outcomes

What the study measures.

Primary outcomes

deterioration

Time frame · 6 years

deterioration rate

Secondary outcomes

Not reported in the indexed record.

Eligibility

Who can take part.

Minimum age
20 Years
Maximum age
85 Years
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: The patients with end-stage lung diseases referral to lung transplantation,Including chronic obstructive pulmonary disease, interstitial lung disease, bronchiectasia Exclusion Criteria: (1) Malignancy (2)Severe cardiovascular diseases (3)Neuromuscular and chest wall deformity (4) Cardiovascular instability (hypotension, arrhythmias, myocardial infarction) (5) Change in mental status; uncooperative patients (6)Renal failure and severe blood electrolyte disturbances

Study locations

1 registered sites.

China. Showing up to 24 locations stored in the fast local snapshot.

Facility not named

Guangzhou, China

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Nesiritide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.